Deliver Your News to the World

US patent 9,051,387: Richard Moss and Ariel Fernandez Create a Molecular Targeted Treatment for Heart Failure

In compromised hearts, muscle contractions are weakened as protein motor myosin tightly binds its regulator MyBP-C. Ariel Fernandez in collaboration with Richard Moss invented a drug that disrupts this association, thereby forestalling heart failure.


Buenos Aires/Buenos Aires/Argentina – WEBWIRE
The scheme describes the molecular action of the invention. The peptide-based drug causes disruption of the molecular brakes that trigger heart failur
The scheme describes the molecular action of the invention. The peptide-based drug causes disruption of the molecular brakes that trigger heart failur

The therapeutic disruption of a protein-protein association is considered one of the most challenging problems in drug discovery. This invention solves the problem, providing a molecular targeted therapy for heart failure.

Ariel Fernandez Consultancy serves the biotechnology industry by harnessing fundamental discoveries to broaden its technological base. In line with this goal, Richard L. Moss in collaboration with Ariel Fernandez invented a new drug for the molecularly targeted treatment of heart failure. By binding competitively to the myosin regulator MyBP-C, the novel drug disrupts the myosin-MyBP-C association, releasing the “molecular brakes” that cause heart failure.

The invention was awarded US patent 9,051,387 and constitutes the first treatment based on rational design. The molecular target was discovered by Richard Moss, while the drug was created by Ariel Fernandez based on molecular engineering concepts like the “dehydron” described in Fernandez’s book “Biomolecular Interfaces” (Springer, 2015).

Ariel Fernandez Consultancy addresses scientific needs of the pharmaceutical industry, seeking to provide the kind of thought leadership that translates into a competitive advantage. The consultancy harnesses novel scientific innovation to design prototypes with optimized safety, controlled specificity and therapeutic potency. 

 


( Press Release Image: http://photos.webwire.com/prmedia/48972/198475/198475-1.gif )


WebWireID198475




 
 Ariel Fernandez
 Heart Failure Treatment
 Biomolecular Interfaces
 Ariel Fernandez Patent
 Biotechnology


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.